Furthermore, other studies have shown that trastuzumab reduced LRR risk among HER2-positive patients with HR-positive stage-I–III BC, whereas patients with HR-negative BC had persistently increased LRR risk despite trastuzumab use (6, 17, 18). The gene discussed is ERBB2; the disease is breast cancer.